| Nom du produit | Sunifiram |
| Synonyms | DM-235; DM235; 1-Benzoyl-4-propanoylpiperazine; 1-(4-Benzoylpiperazin-1-yl)propan-1-one; 1-Benzoyl-4-(1-oxopropyl)piperazine |
| Numéro CAS | 314728-85-3 |
| Formule moléculaire | C₁₄H₁₈N₂O₂ |
| Poids moléculaire | 246.30 g/mol |
| Apparence | Poudre cristalline blanche à blanc cassé |
| Essai (HPLC) | ≥ 99.0% |
| Point de fusion | 86–89°C |
| Perte au séchage | ≤ 0.5% |
| Residue on Ignition | ≤ 0.1% |
| Métaux lourds | ≤ 10 ppm |
| Storage | Cool, dry, sealed, protected from light |
| Shelf Life | 36 months |
Besoin d'aide ? Contacter notre équipe
Sunifiram (developmental code DM-235) is a potent nootropic compound belonging to the piperazine class.
It was developed as a next-generation cognitive enhancer with significantly higher potency than the classic racetam family (piracetam, aniracetam).
Sunifiram is structurally distinct from racetams but shares similar glutamatergic mechanisms.
Sunifiram is estimated to be approximately 1,000 times more potent than piracetam in animal models.
It acts as a positive allosteric modulator of AMPA receptors and may also influence nicotinic acetylcholine receptors (nAChRs).
Unlike many racetams, sunifiram does not require metabolic activation.
Sunifiram Nootropic Supplement
Sunifiram was developed by researchers at the University of Florence, Italy, as part of a series of potent ampakine-like compounds. Along with Unifiram (DM-232), it was designed to overcome the low potency limitations of traditional racetams. Preclinical studies demonstrated cognitive-enhancing effects at microgram-per-kilogram doses—orders of magnitude lower than piracetam (which requires milligram-per-kilogram doses).
Sunifiram exerts its effects primarily through glutamatergic modulation:
| Pathway | Proposed Mechanism | Cognitive Effect |
|---|---|---|
| AMPA receptor positive allosteric modulation | Enhances glutamate-induced currents; increases synaptic plasticity | Memory consolidation, learning, attention |
| Nicotinic acetylcholine receptor (nAChR) modulation | May influence α7 nAChR subtypes (preliminary) | Focus, working memory |
| Cholinergic enhancement | Indirect (via glutamatergic-cholinergic interaction) | Learning, memory |
| Application | Description | End Users |
|---|---|---|
| AMPA receptor research | Studying positive allosteric modulation of AMPA receptors | Academic neuroscience, pharmacology labs |
| Cognitive enhancement studies | In vitro and animal models of memory, learning, attention | Behavioral neuroscience research |
| Scopolamine-induced amnesia models | Reversal of cholinergic deficit (Alzheimer’s research models) | Neuropharmacology, drug discovery |
| Comparative nootropic research | Potency comparisons with racetams and other ampakines | Pharmaceutical R&D |
| Research Focus | Application |
|---|---|
| Piperazine vs. pyrrolidone scaffolds | Comparing structural requirements for AMPA modulation |
| Derivative synthesis | Developing novel sunifiram analogs with improved properties |
| Receptor binding studies | Characterizing AMPA receptor subtype selectivity |
| Application | Description |
|---|---|
| Reference standard | HPLC, LC-MS method development |
| Impurity profiling | For custom synthesis quality control |
| Stability studies | Forced degradation, long-term stability |
LyvBio Co. is a GMP-certified supplier of high-purity Sunifiram for research and development applications.
Capacités d'approvisionnement :
Assay (HPLC): ≥99.0%
Forme : Crystalline powder
Capacité mensuelle : 5+ kg
Quantités en vrac : 1g – 5kg
Délai d'exécution : 3-5 jours (échantillons), 10-15 jours (vrac)
Documentation : COA, MSDS,HNMR, HPLC chromatogram, stability data
L'assurance qualité :
HPLC purity with UV detection
Residual solvents tested (meets USP <467>)
Heavy metals tested (ICP-MS)
Structural confirmation (NMR upon request)
📧 Demandes de renseignements : info@lyvbio.com
| Parameter | Specification | Test Method |
|---|---|---|
| Essai (HPLC) | ≥ 99.0% | HPLC-UV (254 nm) |
| Apparence | Poudre cristalline blanche à blanc cassé | Visual |
| Identification | HPLC retention time, NMR (upon request) | HPLC / NMR |
| Point de fusion | 86–89°C | USP <741> |
| Perte au séchage | ≤ 0.5% | USP <731> |
| Residue on Ignition | ≤ 0.1% | USP <281> |
| Métaux lourds | Pb ≤ 10 ppm; As ≤ 2 ppm; Cd ≤ 1 ppm; Hg ≤ 0.1 ppm | ICP-MS |
| Related Substances | Single impurity ≤ 0.5%; Total ≤ 1.0% | HPLC-UV |
| Residual Solvents | Meet USP <467> | GC |
| Particle Size | 95% through 80 mesh | Sieve Analysis |
Q: Is Sunifiram the same as Piracetam or Aniracetam?
A: No. Sunifiram is a structurally distinct piperazine derivative, not a racetam. It is estimated to be approximately 1,000 times more potent than piracetam in animal models.
Q: Is Sunifiram FDA-approved for medical use?
A: No. Sunifiram has no approved medical use in any major market. It is a research chemical for laboratory use only. No human clinical trials have been published.
Q: What is the difference between Sunifiram and Unifiram (DM-232)?
A: Both are piperazine derivatives developed by the same research group. They have similar potency (~1,000x piracetam) but different chemical structures (different substituents on the piperazine ring). Unifiram is CAS 219694-40-3.
Q: What is the mechanism of action of Sunifiram?
A: Sunifiram is believed to act as a positive allosteric modulator of AMPA receptors (an ampakine). It may also influence nicotinic acetylcholine receptors. Detailed receptor binding studies are limited.
Q: What is the effective dose range in animal studies?
A: Published studies report cognitive-enhancing effects at 0.01–0.1 mg/kg (oral) in rodents—approximately 1,000 times more potent than piracetam.
Q: Are there human clinical trials for Sunifiram?
A: No. No human clinical trials have been published. Sunifiram is a research chemical only.
📧 Courriel : info@lyvbio.com
🌐 Site web : https://www.lyvbio.com
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese